Please Wait
Applying Filters...
menu
    • menu
    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-05-19

    Virtual Booth

    An Enquiry

    Chirogate is a professional Prostaglandin manufacturer.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Darolutamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 14,414Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bayer weathers LOE for Xarelto with success of Kerendia, Nubeqa
    Bayer weathers LOE for Xarelto with success of Kerendia, Nubeqa

    13 May 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/booming-sales-bayers-kerendia-nubeqa-overcome-decline-xarelto

    FIERCE PHARMA
    13 May 2025
    Share Share
    AUA 2025: NUBEQA® + ADT Shows Strong PSA Response in mHSPC
    AUA 2025: NUBEQA® + ADT Shows Strong PSA Response in mHSPC

    29 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250428612520/en/AUA-2025-New-Data-from-Post-Hoc-Analyses-Shared-on-Ultra-Low-Prostate-Specific-Antigen-PSA-Response-in-Patients-with-Metastatic-Hormone-Sensitive-Prostate-Cancer-Receiving-NUBEQA-darolutamide-plus-Androgen-Deprivation-Therapy-ADT

    BUSINESSWIRE
    29 Apr 2025
    Share Share
    Bayer to Present NUBEQA Data at AUA 2025 Meeting
    Bayer to Present NUBEQA Data at AUA 2025 Meeting

    16 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250415454947/en/Bayer-to-Unveil-Latest-NUBEQA-darolutamide-Data-and-Prostate-Cancer-Research-at-American-Urological-Association-AUA-2025-Annual-Meeting

    BUSINESSWIRE
    16 Apr 2025
    Share Share
    Nubeqa Data Reinforce Safety & Efficacy In Prostate Cancer
    Nubeqa Data Reinforce Safety & Efficacy In Prostate Cancer

    13 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250212184233/en

    BUSINESSWIRE
    13 Feb 2025
    Share Share
    RedHill Starts Ph 2 of Opaganib & Darolutamide in Prostate Cancer
    RedHill Starts Ph 2 of Opaganib & Darolutamide in Prostate Cancer

    04 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/redhill-announces-initiation-of-phase-2-study-of-opaganib-and-darolutamide-in-advanced-prostate-cancer-302367315.html

    PR NEWSWIRE
    04 Feb 2025
    Share Share
    Bayer’s pharma growth strategy progressing well as pipeline
    Bayer’s pharma growth strategy progressing well as pipeline

    15 Jan 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/bayers-pharma-growth-strategy-progressing-well-as-pipeline-advances-16667

    INDPHARMAPOST
    15 Jan 2025
    Share Share